ÄÁÅÙÃ÷»ó¼¼º¸±â

COVID-19 ¹ÙÀÌ·¯½º ¼¼Æ÷¿Í ±«»ç¿°Áõ ¿¬±¸
COVID-19 ¹ÙÀÌ·¯½º ¼¼Æ÷¿Í ±«»ç¿°Áõ ¿¬±¸
  • ÀúÀÚBhawna Tomar, Hans-Joachim Anders, Jyaysi Desai, Shrikant R. Mulay Àú
  • ÃâÆÇ»ç¾ÆÁø
  • ÃâÆÇÀÏ2020-07-12
  • µî·ÏÀÏ2020-12-21
º¸À¯ 1, ´ëÃâ 0, ¿¹¾à 0, ´©Àû´ëÃâ 5, ´©Àû¿¹¾à 0

Ã¥¼Ò°³

The COVID-19 pandemic is progressing worldwide with an alarming death toll.
There is an urgent need for novel therapeutic strategies to combat potentially
fatal complications. Distinctive clinical features of severe COVID-19 include acute
respiratory distress syndrome, neutrophilia, and cytokine storm, along with
severe inflammatory response syndrome or sepsis. Here, we propose the
putative role of enhanced neutrophil infiltration and the release of neutrophil
extracellular traps, complement activation and vascular thrombosis during
necroinflammation in COVID-19. Furthermore, we discuss how neutrophilic
inflammation contributes to the higher mortality of COVID-19 in patients with
underlying co-morbidities such as diabetes and cardiovascular diseases. This
perspective highlights neutrophils as a putative target for the immunopathologic
complications of severely ill COVID-19 patients. Development of the novel
therapeutic strategies targeting neutrophils may help reduce the overall disease
fatality rate of COVID-19.

¸ñÂ÷

Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Æ¯¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: È¯°æ¿¡ Áö¼ÓÀûÀΠ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22

Á¦ 2Æí ¿¬±¸³í¹®
Neutrophils and Neutrophil Extracellular Traps Drive
Necroinflammation in COVID-19

1. Abstract 23
2. Introduction 23
3. ACE2 and Neutrophils 24
4. SARS-CoV-2, Neutrophils, and Necroinflammation in
COVID-19 24
5. Diabetes, SARS-CoV-2, and Neutrophils 26
6. Cardiovascular Diseases, SARS-CoV-2, and Neutrophils 27
7. Summary and Perspectives 27
8. References 27

ÇÑÁÙ ¼­Æò